Regeneron’s Global Program Head for Rimbosertamab Discusses Rimbosertamab’s Potential as a First-Line Treatment for Multiple Myeloma

In an interview with Pharm Exec deputy editor Don Tracy, Karen Rodriguez-Lorenc, global program head for Linvoseltamab at Regeneron, talks about Linvoseltamab’s potential to become a frontline treatment for multiple myeloma (MM) and the company’s VelociSuite technology.